Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Pilot, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Study To Evaluate Efficacy, Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Pharmacogenetics of CC-220 In Subjects With Systemic Lupus Erythematosus

NCT02185040 is registered in ClinicalTrials.gov with Celgene as lead sponsor.

NCT NCT02185040
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02185040 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Pilot, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Study To Evaluate Efficacy, Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Pharmacogenetics of CC-220 In Subjects With Systemic Lupus Erythematosus
Lead sponsor
Celgene
Phase
Phase 2
Overall status
Completed
Start date
September 16, 2014
Completion date
September 25, 2018
Enrollment
42 (actual)
Sites
35

Conditions

As the registry lists them; a condition with its own page is linked.

systemic lupus erythematosus